Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer
Authors:
Open Access
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 38 (4) , 516-533.e9
Abstract
No abstract availableKeywords
Funding Information
- Roche
- Bayer
- University of Cambridge
- GlaxoSmithKline
- Pfizer
- AstraZeneca
- Novartis
- National Science Foundation
- International Business Machines Corporation
- Breast Cancer Research Foundation
- V Foundation for Cancer Research
- National Institutes of Health (R01CA190642-01)
- National Institutes of Health (P30 CA008748)
- Stand Up To Cancer
- Cancer Research UK (C197/A28289)
- Genentech
This publication has 74 references indexed in Scilit:
- Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancerOncogenesis, 2013
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variationNucleic Acids Research, 2012
- A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer CellsCancer Cell, 2011
- Kinetic Modeling of Hyperpolarized 13C Label Exchange between Pyruvate and Lactate in Tumor CellsJournal of Biological Chemistry, 2011
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerOncogene, 2011
- FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistanceOncogene, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- PTEN-deficient cancers depend on PIK3CBProceedings of the National Academy of Sciences, 2008